Forsberg A, 2020
Sweden
To investigate how maternal peripheral immunity is affected by pregnancy, and by probiotic and ω-3 fatty acid supple mentation.
R, DB, PC From gestational week 20 until birth
1) L. reuteri + ω-3 PUFA: 22
2) ω-3 PUFA + placebo: 21
3) placebo + ω-3 PUFA: 22
4) placebo capsules + placebo oil: 23 (L. reuteri: 1×109 CFU, 20 droplets × 2 daily; ω-3 PUFA: 3840 mg)
No adverse events were reported in the women receiving L. reuteri.
Abrahamsson T, 2007
Sweden
To evaluate prevention of atopic eczema in infants 0–2 years old where pregnant women ingested L. reuteri ATCC 55730 before giving birth.
R, DB, PC 4 weeks before delivery, follow-up after 1 month
L. reuteri: 95 (1×108 CFU) Placebo: 93
Adverse events among mothers were not registered.
Schlagenhauf U, 2016
Germany
Influence of L. reuteri Prodentis lozenges on plaque control and gingival inflam mation in pregnant women.
R, DB, PC During 3rd trimester and until the first days after delivery
L. reuteri: 24 (4×108 CFU) Placebo: 21
Adverse events were not registered.